surmount trial tirzepatide SURMOUNT-2: confers about 15% weight loss in adults with obesity and diabetes Tirzepatide for the treatment of

This is counterproductive

Common side effects of tirzepatide medications include nausea, diarrhea, and constipation, which generally subside over time as your body adjusts to the medication

The progression moves through 7.5 mg, then 10 mg , then 12.5 mg, and potentially up to 15 mg

Glucagon is a hormone that is released with low blood sugar, prolonged fasting, exercise, and protein rich meals to prevent blood sugar from dropping too low so inhibiting this with stimulating insulin further reduces blood sugar levels Slows the movement of food from the stomach into the small intestine which leads to feeling full faster reducing food intake while eating Acts on GLP1 and GIP centers in the brain suppressing appetite which leads to feeling full longer after eating Increases insulin sensitivity throughout the entire body Weight loss is an off label use of tirzepatide as it is only FDA approved for glycemic control in patients with type 2 diabetes currently

Different three-receptor combinations, different metabolic effects, different dosage considerations